Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.537 USD | -2.01% |
|
+9.88% | -34.65% |
05-30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
05-13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.65% | 19.57M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Forte Biosciences : Truist Securities Downgrades Forte Biosciences to Hold from Buy